CLOs on the Move

Turn Biotechnologies

www.turn.bio

 
Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. We are focused on reprogramming the epigenome – a network of chemical compounds and proteins that control cell functions by influencing which genes are active – to restore capabilities that are often lost with age.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.turn.bio
  • 319 N Bernardo Avenue
    Mountain View, CA USA 94043
  • Phone: 833.887.6246

Executives

Name Title Contact Details

Similar Companies

Provista Life Sciences

Provista Life Sciences is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Thomson Research Associates

Thomson Research Associates is a North York, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Virtual Radiologic Corporation

Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.

Stealth BioTherapeutics

Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondria therapies to patients to treat both common and rare diseases. As a key common element in a variety of serious, debilitating diseases, mitochondria – the cell’s energy source – offer a promising, and yet untapped target to modify diseases with significant unmet treatment needs. Stealth is expanding its clinical development program to additional therapeutic areas, including cardio-renal diseases, ophthalmic disorders and orphan mitochondrial diseases. By defining the broad potential of its mitochondrial platform and therapies, Stealth is leading mitochondrial medicine.